Fred Hutchinson Cancer Research Center, The Netherlands Cancer Institute (NKI), and Cancer Research Technology (CRT) released details of the development and commercialization of a powerful protein-genome interaction mapping technology termed DamID. DamID, developed by scientists at Fred Hutchinson Cancer Research Center and the NKI, maps protein-genome interactions using tethered DNA adenine methyltransferase to create unique tags, which mark binding sites. This technology addresses current limitations of existing techniques to identify in vivo genome binding sites of proteins. CRT has been granted exclusive rights to commercialize this new technology and intends to partner with life science reagents companies. Revenues generated will be shared with the NKI and Fred Hutchinson Cancer Research Center.

Previous articleStratagene and Merck Subsidiary, Rosetta Inpharmatics, Enter into Joint Development and License Agreement; to Develop RNA Purification System for Use in Molecular Diagnostics and Research Applications
Next articleFDA Forms Internal Nanotechnology Task Force